Emergent hits $1.5B valuation with $130M Series C, one year after launch
What's the deal? EmergentDealroom has a profile for this one. Try Dealroom →, an agentic AI platform that lets founders and businesses build full-stack web and mobile applications without code, has raised $130 million in a Series C round. The round valued the startup at $1.5 billion, making it a unicorn about a year after launch.
Who's backing it? The round was co-led by private equity firm CreaegisDealroom has a profile for this one. Try Dealroom →, Manipal GroupDealroom has a profile for this one. Try Dealroom →'s Claypond, and Sentinel GlobalDealroom has a profile for this one. Try Dealroom →. Existing investors Khosla Ventures, SoftBank Vision Fund 2, Lightspeed, and Y Combinator also took part.
What's the endgame? Emergent uses a team of specialised AI agents to write, test, and deploy applications in the cloud, letting users build CRMs, ERPs, marketplaces, and internal tools. Chief executive officer Mukund Jha said the company wants to move beyond coding to become "an operating system for businesses," helping small firms automate internal workflows.
Why now? The new valuation is a fivefold jump from about $300 million in January. "Since our last fundraise, we have almost grown 4x in business — both in users and revenue," Jha said, pointing to improved customer acquisition costs, gross margins, and high retention.
The backstory: Jha, who previously co-founded delivery platform Dunzo, launched Emergent in 2025 with his brother Madhav Jha, a former Dropbox machine learning engineer. The Series C takes total funding to $230 million, following a $70 million Series B in January, a $23 million Series A, and a $7 million seed round.
The signal: Emergent's rapid climb reflects investor appetite for agentic AI tools that automate software development for non-technical users. The pace — four rounds and unicorn status inside roughly a year — signals how quickly capital is flowing to startups betting on AI agents as the next software layer.
Read more: htsyndication.com